OCDNCT03313622
Locating Biomarkers in OCD Through Behavioral Tasks
An observational study of OCD and Obsessive-Compulsive Disorder, run by Baylor College of Medicine at 3 sites in United States.
Trial summary
Subjects that have a diagnosis of OCD will participate in a clinical interview and cognitive tasks, during which they will be exposed to their individual OC stressors or will be asked to make decisions related to information value and quantity while measuring neural activity and filming facial reactions. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- OCD, Obsessive-Compulsive Disorder
- What is being tested?
- Beads Task and PROVOC Tasks
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 20 participants
- Where
- 3 sitesUnited States
- Study dates
- Mar 2027to Mar 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Potential subjects are patients diagnosed with OCD meeting the inclusion/exclusion criteria above.
Who may be able to join
- Diagnosis of OCD
- Non-pregnant if female
- Minimum score of 16 on Y-BOCS
- Ability to provide informed consent
Who cannot join
- Those not meeting inclusion criteria listed above
- Lifetime diagnosis of psychotic disorders such as schizophrenia
- Alcohol or substance abuse/dependence within 6 months, excluding nicotine
- Deemed at high risk of suicidal behavior or impulsivity
- Pregnant or plans to become pregnant in the next 24 months
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States3 sites
Baylor College of Medicine
Houston, Texas, 77030
Clarissa Aguilar, (713) 798-3080, Clarissa.Aguilar@bcm.edu
Gregory Vogt, (713) 798-4729, gsvogt@bcm.edu
University of Pittsburgh
Pittsburgh, Pennsylvania, 15260
Brown University
Providence, Rhode Island, 02912
About this study
Official title: Locating Biomarkers of Medically Intractable Obsessive Compulsive Disorder (OCD) Through the Use of Behavioral Tasks
Subjects that have a diagnosis of OCD will participate in a clinical interview and cognitive tasks, during which they will be exposed to their individual OC stressors or will be asked to make decisions related to information value and quantity while measuring neural activity and filming facial reactions. This will assist investigators to look for biomarkers of that change. This study offers a unique opportunity to develop biomarkers for key domains of OCD, and other neuropsychiatric disorders, that are grounded in brain neurocircuitry at the individual-patient level.
Subjects will participate in a clinical interview (Day 1), and then tasks+EEG (Day 2). Day 1 will be 4 hours or less, and Day 2 will be 2.5 hours or less.
Read the detailed description
This is a research study in which BCM is collaborating with Brown University/Butler Hospital and University of Pittsburgh. BCM and Butler Hospital will be enrolling sites. Brown University and University of Pittsburgh will be analyzing the assessment, EEG and facial recognition data.
Subjects will participate in a clinical interview (Day 1), and cognitive tasks with EEG (Day 2).
Neural data (through EEG) will be collected from OCD subjects when their symptoms are provoked, so we can look for biomarkers of that change. The subjects will be monitored through EEG and video recording for facial recognition. After initial video and EEG setup subjects will complete the Beads task followed by the Provocation task.
Day 1:
Demographics Questionnaire. Assesses psychiatric and medical treatment history.
SCID-5: Structured Clinical Interview for the DSM 5 (SCID): The SCID will be used to determine comorbid diagnoses at baseline.
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS): The YBOCS is a 10-item inventory that assesses severity of OCD symptoms
Y-BOCS Symptom Checklist: The YBOCS symptom checklist assesses OCD symptom subtypes.
Trait Core Dimensions Questionnaire (TCDQ): The TCDQ measures prevalence of harm avoidant or incompleteness traits related to OCD.
Beck Anxiety Inventory (BAI). The BAI is a 21-question self-report inventory that is used for measuring the severity of anxiety. The questions used in this measure ask about common symptoms of anxiety that the participant has had during the past week.
Beck Depression Inventory (BDI): The BDI is a 21-question self-report inventory designed to measure depression severity.
Beads Task:
Participants will be asked to make a series of categorical decisions that involve combining information about the value and probability of potential rewards. Subjects will sit in front of a computer monitor and place their hand over a box with orange and blue button that they will be asked to press based on their idea of which one will be the majority in a jar full of orange and blue beads. This task is designed to dissociate information value and quantity as the guesses are made based on information shown to the subject. Combining asymmetric rewards beads task with neuroimaging could dissociate neural signals related to information value from those related to information quantity. That is the goal here as we track neural activity through EEG measurements and facial recognition through video acquisition. This task should take 15-20 minutes to complete, not including EEG setup.
Provocation of OC symptoms (PROVOC):
PROVOC will be used to evoke manageable levels of OCD related distress. Three tasks will be developed collaboratively with the participant and independent evaluator that involve the participant being exposed in vivo to triggers that are considered by him/her impossible to confront without ritualizing. Each of the 3 tasks will be broken up into 7 steps, which provoke increasing levels of distress when encountered. Each step will be uniform in duration (i.e., one minute exposure) with the potential of 7 one-minute tasks with ~30 seconds break between steps, to provide brief rest for the patient and introduction of the next task. Participants will systematically confront triggers without ritualizing starting with easier items, and will continue until they feel their distress or need to ritualize is intolerable. This task will involve researchers and subjects deciding upon a few different triggering items (bloody (fake) napkin, used tissue, etc) that will be moved closer and closer to the subject as they wear the EEG measuring system. Each step should take one minute or less, and the subject will always have the option of stopping if the task becomes too distressing. There will also be a similar process involving objects that should not cause any distress to be used as a control. Consistent with prior research, 5 scores are calculated including percentage of steps completed, subjective units of distress (SUDS) across steps, avoidance, ritual engagement, and composite provocation score, which will be associated with changes in biosignature from brain recordings. We will pilot the provocation protocol, and start addressing problems that come up (e.g. EEG movement artifacts). Sessions will be videotaped with AFAR system concurrent to recording of LFPs from VS and scalp EEG.
High-density EEG System:
The g.BCIsys64USB EEG system, manufactured by g.tec GmBH, uses wide-range DC-coupled amplifier technology with 24-bit sampling, which results in an input voltage resolution of < 30 nV. Very efficient analog-to-digital converters (2.5 MHz per channel) result in very high signal to noise ratio, critical for recording subtle changes in EEG measures. The system combines four bio-amplifiers (16-channels each) that can either be stacked to provide a higher density (32/48/64 channels) system, or can simultaneously be used on different study participants. The EEG system makes use of 'active' electrode technology that employs an additional ultra-low noise pre-amplifier located inside each electrode to maximize the signal-to-noise ratio. The active electrodes work in a frequency range from 0 - 10 kHz (DC) or 0.1 - 10 kHz (AC). The EEG system is also equipped with innovative data acquisition and data analysis software that allows sophisticated signal processing and data analysis capabilities. The system includes a 3D scalp digitizer that maps the scalp in the stereotactic space for EEG source localization. Other capabilities of the system include eye-tracking and acquisition of physiological data (SpO2, pulse and skin conductance).
Automated Facial Affect Recognition (AFAR) will be used to measure facial expression of positive and negative valence. AFAR is a computer-vision based approach that can objectively measure the occurrence, intensity, laterality, and timing of facial action units, head pose, and gaze at video frame rate (30 to 60 frames per second). Participants will be videotaped. Action units are anatomically based actions that individually or in combination can describe nearly all-possible facial expressions. AFAR has strong concurrent validity with manual measurement of facial action units, holistic expressions, depression severity, and psychological distress; and with ground truth measures of head pose and gaze. Previous research has identified action units associated with positive (e.g., enjoyment) and negative (e.g., fear, anger, disgust, and anxiety) emotion; and used them to represent scales for positive and negative valence and pain. Because gaze and head orientation also are strongly related to emotion and valence, we include them in positive and negative valence scales. Videotaped data will be shared with the University of Pittsburgh.
Local data and safety monitoring will be conducted by the PI who will meet regularly with the study team to review new information from clinical ratings, assessments, and medical records for each subject. Study-related adverse events or threats to subject confidentiality will be monitored, and any needed safety changes will be addressed. Assessment of adverse events, including grading of severity and attribution to research, will be conducted at each visit and noted on the rating coversheet. The PI will report all unanticipated problems within 5 working days from becoming aware of the event. The PI will evaluate all adverse events and determine whether the event affects the Risk/Benefit ratio of the study, and whether modifications to the protocol or consent form are required.
- Conditions
- OCD, Obsessive-Compulsive Disorder
- Being tested
- Beads Task, PROVOC Tasks
- Keywords
- OCD, Obsessive Compulsive Disorder
- Medical subject headings
- Obsessive-Compulsive Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Beads TaskBehavioural
Participants will be asked to make a series of decisions that involve combining information about the value and probability of potential rewards. Subjects will sit in front of a computer monitor and place their hand over a box with orange and blue button that they will be asked to press based on their idea of which one will be the majority in a jar full of orange and blue beads. This task should take 15-20 minutes to complete, not including EEG setup.
PROVOC TasksBehavioural
Three tasks will be developed collaboratively with the participant and independent evaluator that involve the participant being exposed to triggers that are considered by him/her impossible to confront without ritualizing. There will also be a similar process involving objects that should not cause any distress to be used as a control. Sessions will be videotaped with AFAR system concurrent to recording of LFPs from VS and scalp EEG.
| Study group | Role | What they receive |
|---|---|---|
| OCD group | Day 1: Questionnaires/Assessments
Day 2: Tasks Receives: Behavioral: Beads Task; Behavioral: PROVOC Tasks |
What is being measured
The primary outcome is the main question the study is designed to answer.
Investigate for biomarkers of obsessive compulsive disorder pathophysiology through the use of behavioral tasks - Beads task
Subject will perform beads task while EEG and videotape monitors neural and facial data throughout
Measured: Day 2
Investigate for biomarkers of obsessive compulsive disorder pathophysiology through the use of behavioral tasks - PROVOC Task 1
Subject will undergo PROVOC Task 1 with Item 1 of 3 that may invoke OCD triggers while EEG and videotape monitors neural and facial data throughout
Measured: Day 2
Investigate for biomarkers of obsessive compulsive disorder pathophysiology through the use of behavioral tasks - PROVOC Task 2
Subject will undergo PROVOC Task 2 with Item 2 of 3 that may invoke OCD triggers while EEG and videotape monitors neural and facial data throughout
Measured: Day 2
Investigate for biomarkers of obsessive compulsive disorder pathophysiology through the use of behavioral tasks - PROVOC Task 3
Subject will undergo PROVOC Task 3 with Item 3 of 3 that may invoke OCD triggers while EEG and videotape monitors neural and facial data throughout
Measured: Day 2
Investigate for biomarkers of obsessive compulsive disorder pathophysiology through the use of behavioral tasks - Non-PROVOC Task 1
Subject will undergo the same exposure task with Item 1 of 3 that does not invoke OCD triggers while EEG and videotape monitors neural and facial data throughout
Measured: Day 2
Investigate for biomarkers of obsessive compulsive disorder pathophysiology through the use of behavioral tasks - Non-PROVOC Task 2
Subject will undergo the same exposure task with Item 2 of 3 that does not invoke OCD triggers while EEG and videotape monitors neural and facial data throughout
Measured: Day 2
Investigate for biomarkers of obsessive compulsive disorder pathophysiology through the use of behavioral tasks - Non-PROVOC Task 3
Subject will undergo the same exposure task with Item 3 of 3 that does not invoke OCD triggers while EEG and videotape monitors neural and facial data throughout
Measured: Day 2
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Oct 2017
- Study startMar 2027 (estimated)
- Primary completionMar 2028 (estimated)
- Study completionMar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OCDStudies of the same condition, open and under way.
- More trials run by Baylor College of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Baylor College of Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- Brown University, University of Pittsburgh, Butler Hospital
- Responsible party
- Principal investigator, Wayne Goodman MD, Baylor College of Medicine
- Investigators
- Wayne Goodman, MD, Principal investigator, Baylor College of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03313622
- Sponsor's protocol ID
- H42237
- Status last verified
- Jun 2026
- First submitted
- 13 Oct 2017
- Last updated
- 30 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 30 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Locating Biomarkers of Medically Intractable Obsessive Compulsive Disorder (OCD) Through the Use of Behavioral Tasks
- ClinicalTrials.gov ID
- NCT03313622
- Acronym / sponsor ID
- H42237
- Conditions
- OCD, Obsessive-Compulsive Disorder
- Keywords
- OCD, Obsessive Compulsive Disorder
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Baylor College of MedicineUniversity, hospital or other
- Collaborators
- Brown University, University of Pittsburgh, Butler Hospital
- Study start
- Mar 2027 (estimated)
- Primary completion
- Mar 2028 (estimated)
- Study completion
- Mar 2028 (estimated)
- First posted
- 18 Oct 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Subjects that have a diagnosis of OCD will participate in a clinical interview and cognitive tasks, during which they will be exposed to their individual OC stressors or will be asked to make decisions related to information value and quantity while measuring neural activity and filming facial reactions. This will assist investigators to look for biomarkers of that change. This study offers a unique opportunity to develop biomarkers for key domains of OCD, and other neuropsychiatric disorders, that are grounded in brain neurocircuitry at the individual-patient level.
Subjects will participate in a clinical interview (Day 1), and then tasks+EEG (Day 2). Day 1 will be 4 hours or less, and Day 2 will be 2.5 hours or less.
Detailed description
This is a research study in which BCM is collaborating with Brown University/Butler Hospital and University of Pittsburgh. BCM and Butler Hospital will be enrolling sites. Brown University and University of Pittsburgh will be analyzing the assessment, EEG and facial recognition data.
Subjects will participate in a clinical interview (Day 1), and cognitive tasks with EEG (Day 2).
Neural data (through EEG) will be collected from OCD subjects when their symptoms are provoked, so we can look for biomarkers of that change. The subjects will be monitored through EEG and video recording for facial recognition. After initial video and EEG setup subjects will complete the Beads task followed by the Provocation task.
Day 1:
Demographics Questionnaire. Assesses psychiatric and medical treatment history.
SCID-5: Structured Clinical Interview for the DSM 5 (SCID): The SCID will be used to determine comorbid diagnoses at baseline.
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS): The YBOCS is a 10-item inventory that assesses severity of OCD symptoms
Y-BOCS Symptom Checklist: The YBOCS symptom checklist assesses OCD symptom subtypes.
Trait Core Dimensions Questionnaire (TCDQ): The TCDQ measures prevalence of harm avoidant or incompleteness traits related to OCD.
Beck Anxiety Inventory (BAI). The BAI is a 21-question self-report inventory that is used for measuring the severity of anxiety. The questions used in this measure ask about common symptoms of anxiety that the participant has had during the past week.
Beck Depression Inventory (BDI): The BDI is a 21-question self-report inventory designed to measure depression severity.
Beads Task:
Participants will be asked to make a series of categorical decisions that involve combining information about the value and probability of potential rewards. Subjects will sit in front of a computer monitor and place their hand over a box with orange and blue button that they will be asked to press based on their idea of which one will be the majority in a jar full of orange and blue beads. This task is designed to dissociate information value and quantity as the guesses are made based on information shown to the subject. Combining asymmetric rewards beads task with neuroimaging could dissociate neural signals related to information value from those related to information quantity. That is the goal here as we track neural activity through EEG measurements and facial recognition through video acquisition. This task should take 15-20 minutes to complete, not including EEG setup.
Provocation of OC symptoms (PROVOC):
PROVOC will be used to evoke manageable levels of OCD related distress. Three tasks will be developed collaboratively with the participant and independent evaluator that involve the participant being exposed in vivo to triggers that are considered by him/her impossible to confront without ritualizing. Each of the 3 tasks will be broken up into 7 steps, which provoke increasing levels of distress when encountered. Each step will be uniform in duration (i.e., one minute exposure) with the potential of 7 one-minute tasks with ~30 seconds break between steps, to provide brief rest for the patient and introduction of the next task. Participants will systematically confront triggers without ritualizing starting with easier items, and will continue until they feel their distress or need to ritualize is intolerable. This task will involve researchers and subjects deciding upon a few different triggering items (bloody (fake) napkin, used tissue, etc) that will be moved closer and closer to the subject as they wear the EEG measuring system. Each step should take one minute or less, and the subject will always have the option of stopping if the task becomes too distressing. There will also be a similar process involving objects that should not cause any distress to be used as a control. Consistent with prior research, 5 scores are calculated including percentage of steps completed, subjective units of distress (SUDS) across steps, avoidance, ritual engagement, and composite provocation score, which will be associated with changes in biosignature from brain recordings. We will pilot the provocation protocol, and start addressing problems that come up (e.g. EEG movement artifacts). Sessions will be videotaped with AFAR system concurrent to recording of LFPs from VS and scalp EEG.
High-density EEG System:
The g.BCIsys64USB EEG system, manufactured by g.tec GmBH, uses wide-range DC-coupled amplifier technology with 24-bit sampling, which results in an input voltage resolution of < 30 nV. Very efficient analog-to-digital converters (2.5 MHz per channel) result in very high signal to noise ratio, critical for recording subtle changes in EEG measures. The system combines four bio-amplifiers (16-channels each) that can either be stacked to provide a higher density (32/48/64 channels) system, or can simultaneously be used on different study participants. The EEG system makes use of 'active' electrode technology that employs an additional ultra-low noise pre-amplifier located inside each electrode to maximize the signal-to-noise ratio. The active electrodes work in a frequency range from 0 - 10 kHz (DC) or 0.1 - 10 kHz (AC). The EEG system is also equipped with innovative data acquisition and data analysis software that allows sophisticated signal processing and data analysis capabilities. The system includes a 3D scalp digitizer that maps the scalp in the stereotactic space for EEG source localization. Other capabilities of the system include eye-tracking and acquisition of physiological data (SpO2, pulse and skin conductance).
Automated Facial Affect Recognition (AFAR) will be used to measure facial expression of positive and negative valence. AFAR is a computer-vision based approach that can objectively measure the occurrence, intensity, laterality, and timing of facial action units, head pose, and gaze at video frame rate (30 to 60 frames per second). Participants will be videotaped. Action units are anatomically based actions that individually or in combination can describe nearly all-possible facial expressions. AFAR has strong concurrent validity with manual measurement of facial action units, holistic expressions, depression severity, and psychological distress; and with ground truth measures of head pose and gaze. Previous research has identified action units associated with positive (e.g., enjoyment) and negative (e.g., fear, anger, disgust, and anxiety) emotion; and used them to represent scales for positive and negative valence and pain. Because gaze and head orientation also are strongly related to emotion and valence, we include them in positive and negative valence scales. Videotaped data will be shared with the University of Pittsburgh.
Local data and safety monitoring will be conducted by the PI who will meet regularly with the study team to review new information from clinical ratings, assessments, and medical records for each subject. Study-related adverse events or threats to subject confidentiality will be monitored, and any needed safety changes will be addressed. Assessment of adverse events, including grading of severity and attribution to research, will be conducted at each visit and noted on the rating coversheet. The PI will report all unanticipated problems within 5 working days from becoming aware of the event. The PI will evaluate all adverse events and determine whether the event affects the Risk/Benefit ratio of the study, and whether modifications to the protocol or consent form are required.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| OCD group | – | Behavioral: Beads Task, Behavioral: PROVOC TasksDay 1: Questionnaires/Assessments Day 2: Tasks |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Potential subjects are patients diagnosed with OCD meeting the inclusion/exclusion criteria above.
Key inclusion criteria (4 listed)
- Diagnosis of OCD
- Non-pregnant if female
- Minimum score of 16 on Y-BOCS
- Ability to provide informed consent
Key exclusion criteria (5 listed)
- Those not meeting inclusion criteria listed above
- Lifetime diagnosis of psychotic disorders such as schizophrenia
- Alcohol or substance abuse/dependence within 6 months, excluding nicotine
- Deemed at high risk of suicidal behavior or impulsivity
- Pregnant or plans to become pregnant in the next 24 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Beads TaskParticipants will be asked to make a series of decisions that involve combining information about the value and probability of potential rewards. Subjects will sit in front of a computer monitor and place their hand over a box with orange and blue button that they will be asked to press based on their idea of which one will be the majority in a jar full of orange and blue beads. This task should take 15-20 minutes to complete, not including EEG setup. | Behavioural | OCD group |
| PROVOC TasksThree tasks will be developed collaboratively with the participant and independent evaluator that involve the participant being exposed to triggers that are considered by him/her impossible to confront without ritualizing. There will also be a similar process involving objects that should not cause any distress to be used as a control. Sessions will be videotaped with AFAR system concurrent to recording of LFPs from VS and scalp EEG. | Behavioural | OCD group |
Primary outcome
Investigate for biomarkers of obsessive compulsive disorder pathophysiology through the use of behavioral tasks - Beads task
Time frame: Day 2
Subject will perform beads task while EEG and videotape monitors neural and facial data throughout
Investigate for biomarkers of obsessive compulsive disorder pathophysiology through the use of behavioral tasks - PROVOC Task 1
Time frame: Day 2
Subject will undergo PROVOC Task 1 with Item 1 of 3 that may invoke OCD triggers while EEG and videotape monitors neural and facial data throughout
Investigate for biomarkers of obsessive compulsive disorder pathophysiology through the use of behavioral tasks - PROVOC Task 2
Time frame: Day 2
Subject will undergo PROVOC Task 2 with Item 2 of 3 that may invoke OCD triggers while EEG and videotape monitors neural and facial data throughout
Investigate for biomarkers of obsessive compulsive disorder pathophysiology through the use of behavioral tasks - PROVOC Task 3
Time frame: Day 2
Subject will undergo PROVOC Task 3 with Item 3 of 3 that may invoke OCD triggers while EEG and videotape monitors neural and facial data throughout
Investigate for biomarkers of obsessive compulsive disorder pathophysiology through the use of behavioral tasks - Non-PROVOC Task 1
Time frame: Day 2
Subject will undergo the same exposure task with Item 1 of 3 that does not invoke OCD triggers while EEG and videotape monitors neural and facial data throughout
Investigate for biomarkers of obsessive compulsive disorder pathophysiology through the use of behavioral tasks - Non-PROVOC Task 2
Time frame: Day 2
Subject will undergo the same exposure task with Item 2 of 3 that does not invoke OCD triggers while EEG and videotape monitors neural and facial data throughout
Investigate for biomarkers of obsessive compulsive disorder pathophysiology through the use of behavioral tasks - Non-PROVOC Task 3
Time frame: Day 2
Subject will undergo the same exposure task with Item 3 of 3 that does not invoke OCD triggers while EEG and videotape monitors neural and facial data throughout
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jun 2026.
- Individual participant dataSharing planned: Undecided
Related trials for OCD
Not yet recruiting
Linear Accelerator Radiosurgical Anterior Capsulotomy With Task-based fMRI Identification of PERSonalized and PrEdictiVE Biomarkers of REsponse in Treatment-Refractory Obsessive-Compulsive Disorder (PERSEVERE Trial)
Treatment-refractory Obsessive-compulsive Disorder (trOCD)
Recruiting
tDCS Associated With Symptom Provocation in the Management of Patients With Resistant Obsessive Compulsive Disorder
Obsessive-Compulsive Disorder
Recruiting
Mindfulness Intervention for Psychological and Family Dynamics in Children With Body-Focused Repetitive Behaviors
Mindfulness Skills, Psychosocial Education
Not yet recruiting
tDCS and Symptom Provocation in Treatment-Resistant OCD
Obsessive - Compulsive Disorder
RecruitingPhase 2
SONATA Dose Duration LIFU for OCD
Obsessive - Compulsive Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Wayne Goodman, MD principal investigator
Baylor College of Medicine
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of OCD and Obsessive-Compulsive Disorder, run by Baylor College of Medicine at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clarissa Aguilar (713-798-3080, Clarissa.Aguilar@bcm.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Investigate for biomarkers of obsessive compulsive disorder pathophysiology through the use of behavioral tasks - Beads task (time frame: Day 2). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2026.